Related Experiment Video
Updated: Oct 4, 2025
06:01
A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia
Published on: August 18, 2015
15.0K
Sex differences in thrombosis as it affects acute ischemic stroke
Shahid M Nimjee1, Asad S Akhter1, Amanda Zakeri1
1Department of Neurosurgery, The Ohio State University College of Medicine, Columbus, OH, United States of America.
Neurobiology of Disease
|February 3, 2022
Summary
Ischemic stroke impacts 800,000 Americans annually. This review explores clot formation, sex differences in stroke, and novel therapies like von Willebrand Factor (vWF) for better patient outcomes.
Area of Science:
- Neurology
- Cardiovascular Medicine
- Hematology
Background:
- Ischemic stroke is a leading cause of death and disability in the US, affecting 800,000 people yearly.
- While historically considered a male condition, stroke disproportionately affects women, who also experience worse outcomes.
- Current acute therapies like mechanical thrombectomy show promise, but long-term neurological deficits persist.
Purpose of the Study:
- To review the mechanisms of thrombosis in ischemic stroke.
- To highlight significant sex differences in stroke incidence, outcomes, and treatment response.
- To discuss emerging therapeutic strategies for thrombolysis, focusing on von Willebrand Factor (vWF).
Main Methods:
- Literature review of current research on ischemic stroke.
- Analysis of epidemiological data regarding sex differences in stroke.
- Examination of recent studies on novel thrombolytic agents and targets.
Main Results:
- Thrombosis is central to ischemic stroke pathophysiology.
- Women face greater stroke burden and poorer outcomes compared to men.
- Mechanical and pharmacological reperfusion are critical, yet long-term sequelae remain.
Conclusions:
- Understanding sex-based differences in thrombosis is crucial for stroke management.
- Targeting factors like vWF may offer new avenues for stroke therapy.
- Further research into novel thrombolytic approaches is needed to improve long-term patient recovery.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
975
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
975
01:29Venous Thrombosis III: Interprofessional Care
44
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
44
01:24Disorders of Hemostasis
1.3K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.3K
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
54
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
54
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.4K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.4K
01:30Venous Thrombosis I: Introduction
60
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
60